X0306 4 2012-11-12 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001528185 Torley Helen C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2012-11-12 4 M 0 7000 33.70 A 50259 D Common Stock 2012-11-12 4 M 0 1250 37.68 A 51509 D Common Stock 2012-11-12 4 S 0 11997 75.22 D 39512 D Stock Option (Right to Buy) 33.70 2012-11-12 4 M 0 7000 0.00 D 2021-08-28 Common Stock 7000 77000 D Stock Option (Right to Buy) 37.68 2012-11-12 4 M 0 1250 0.00 D 2022-03-29 Common Stock 1250 17050 D Shares sold pursuant to a 10b5-1 plan. The shares were sold at prices ranging from $75.00 to $75.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Twenty-Five percent of the shares subject to the option became exercisable one year from the date of grant and become exercisable at a rate of 1/48th per month thereafter. 12.5% of the shares subject to the option became exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Matthew K. Fust, Attorney-in-fact 2012-11-14